- Home
- CLOV vs AUPH Comparison
CLOV vs AUPH Comparison
Compare CLOV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLOV | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CLOV | AUPH |
|---|---|---|
| Price | $4.32 | $15.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.90 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 5.3M | 1.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.03 | ★ 5075.00 |
| EPS | 0.05 | ★ 0.25 |
| Revenue | ★ $1,924,308,000.00 | $283,055,000.00 |
| Revenue This Year | $52.59 | $17.54 |
| Revenue Next Year | $15.37 | $15.74 |
| P/E Ratio | $86.40 | ★ $61.40 |
| Revenue Growth | ★ 40.34 | 20.38 |
| 52 Week Low | $1.58 | $8.80 |
| 52 Week High | $5.59 | $19.25 |
Technical Indicators
Market Signals| Indicator | CLOV | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 44.99 |
| Support Level | $1.96 | $15.43 |
| Resistance Level | $5.18 | $16.38 |
| Average True Range (ATR) | 0.25 | 0.55 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 3.73 | 29.59 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.